#BEGIN_DRUGCARD DB08889

# AHFS_Codes:
10:00

# ATC_Codes:
L01XX45

# Absorption:
Cmax, single IV dose of 27 mg/m^2 = 4232 ng/mL; 
AUC, single IV dose of 27 mg/m^2 = 379 ng•hr/mL;
Carfilzomib does not accumulation in the systemic. At doses between 20 and 36 mg/m2, there was a dose-dependent increase in exposure.

# Biotransformation:
Carfilzomib was rapidly and extensively metabolized by the liver. The predominant metabolites were the peptide fragments and the diol of carfilzomib which suggests that the main metabolic pathways are peptidase cleavage and epoxide hydrolysis. The cytochrome P450 enzyme system is minimally involved in the metabolism of carfilzomib. All metabolites are inactive.

# Brand_Mixtures:
Not Available

# Brand_Names:
Kyprolis

# CAS_Registry_Number:
868540-17-4

# ChEBI_ID:
65347

# Chemical_Formula:
C40H57N5O7

# Chemical_IUPAC_Name:
(2S)-4-methyl-N-[(1S)-1-{[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]carbamoyl}-2-phenylethyl]-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]-4-phenylbutanamido]pentanamide

# Chemical_Structure:
Not Available

# Creation_Date:
2013-05-29 16:03:16 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved on July 20, 2012.

# Dosage_Forms:
Injection, powder, lyophilized, for solution	Intravenous

# Drug_Category:
Antineoplastic

# Drug_Interactions:
Not Available

# Drug_Reference:
17591945	Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ: Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007 Nov 1;110(9):3281-90. Epub 2007 Jun 25.
23393020	Kortuem KM, Stewart AK: Carfilzomib. Blood. 2013 Feb 7;121(6):893-7. doi: 10.1182/blood-2012-10-459883.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Insoluble

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Carfilzomib

# HET_ID:
Not Available

# Half_Life:
Following intravenous administration of doses ≥ 15 mg/m^2, carfilzomib was rapidly cleared from the systemic circulation with a half-life of ≤ 1 hour on Day 1 of Cycle 1.

# InChI_Identifier:
InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1

# InChI_Key:
InChIKey=BLMPQMFVWMYDKT-NZTKNTHTSA-N

# Indication:
Carfilzomib is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D08880

# LIMS_Drug_ID:
8905

# Mechanism_Of_Action:
Carfilzomib is made up of four modified peptides and acts as a proteasome inhibitor. Carfilzomib irreversibly and selectively binds to N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome.  This 20S core has 3 catalytic active sites: the chymotrypsin, trypsin, and caspase-like sites. Inhibition of the chymotrypsin-like site by carfilzomib (β5 and β5i subunits) is the most effective target in decreasing cellular proliferation, ultimately resulting in cell cycle arrest and apoptosis of cancerous cells. At higher doses, carfilzomib will inhibit the trypsin-and capase-like sites.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
719.9099

# Molecular_Weight_Mono:
719.425799203

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Intravenous carfilzomib administration resulted in suppression of proteasome chymotrypsin-like activity when measured in blood 1 hour after the first dose. On Day 1 of Cycle 1, proteasome inhibition in peripheral blood mononuclear cells (PBMCs) ranged from 79% to 89% at 15 mg/m2, and from 82% to 83% at 20 mg/m2. In addition, carfilzomib administration resulted in inhibition of the LMP2 and MECL1 subunits of the immunoproteasome ranging from 26% to 32% and 41% to 49%, respectively, at 20 mg/m2.  Proteasome inhibition was maintained for ≥ 48 hours following the first dose of carfilzomib for each week of dosing. Resistance against carfilzomib has been observed and although the mechanism has not been confirmed, it is thought that up-regulation of P-glycoprotein may be a contributing factor. Furthermore, studies suggest that carfilzomib is more potent than bortezomib.

# Predicted_LogP_Hydrophobicity:
3.21

# Predicted_LogS:
-5.2

# Predicted_Water_Solubility:
4.84e-03 g/l

# Primary_Accession_No:
DB08889

# Protein_Binding:
Over the concentration range of 0.4 - 4 micromolar, carfilzomib was 97% protein bound.

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/kyprolis-drug.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
PR-171

# Synthesis_Reference:
Not Available

# Toxicity:
Most commonly reported adverse reactions (incidence ≥ 30%) are fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, and pyrexia. The two dose limiting toxicities are thrombocytopenia and febrile neutropenia. 
Maximum tolerate dose = 15 mg/m^2

# Update_Date:
2013-05-29 23:57:57 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Carfilzomib

# pKa_Isoelectric_Point:
3.5

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
23393020	Kortuem KM, Stewart AK: Carfilzomib. Blood. 2013 Feb 7;121(6):893-7. doi: 10.1182/blood-2012-10-459883.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
PSMB5

# Drug_Target_1_GenBank_ID_Gene:
D29011

# Drug_Target_1_GenBank_ID_Protein:
558526

# Drug_Target_1_GeneCard_ID:
PSMB5

# Drug_Target_1_Gene_Name:
PSMB5

# Drug_Target_1_Gene_Sequence:
>627 bp
ATGCTTCATGGAACAACCACCCTGGCCTTCAAGTTCCGCCATGGAGTCATAGTTGCAGCT
GACTCCAGGGCTACAGCGGGTGCTTACATTGCCTCCCAGACGGTGAAGAAGGTGATAGAG
ATCAACCCATACCTGCTAGGCACCATGGCTGGGGGCGCAGCGGATTGCAGCTTCTGGGAA
CGGCTGTTGGCTCGGCAATGTCGAATCTATGAGCTTCGAAATAAGGAACGCATCTCTGTA
GCAGCTGCCTCCAAACTGCTTGCCAACATGGTGTATCAGTACAAAGGCATGGGGCTGTCC
ATGGGCACCATGATCTGTGGCTGGGATAAGAGAGGCCCTGGCCTCTACTACGTGGACAGT
GAAGGGAACCGGATTTCAGGGGCCACCTTCTCTGTAGGTTCTGGCTCTGTGTATGCATAT
GGGGTCATGGATCGGGGCTATTCCTATGACCTGGAAGTGGAGCAGGCCTATGATCTGGCC
CGTCGAGCCATCTACCAAGCCACCTACAGAGATGCCTACTCAGGAGGTGCAGTCAACCTC
TACCACGTGCGGGAGGATGGCTGGATCCGAGTCTCCAGTGACAATGTGGCTGATCTACAT
GAGAAGTATAGTGGCTCTACCCCCTGA

# Drug_Target_1_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_1_General_References:
2306472	Lee LW, Moomaw CR, Orth K, McGuire MJ, DeMartino GN, Slaughter CA: Relationships among the subunits of the high molecular weight proteinase, macropain (proteasome). Biochim Biophys Acta. 1990 Feb 9;1037(2):178-85.
7820546	Belich MP, Glynne RJ, Senger G, Sheer D, Trowsdale J: Proteasome components with reciprocal expression to that of the MHC-encoded LMP proteins. Curr Biol. 1994 Sep 1;4(9):769-76.
7864893	Kristensen P, Johnsen AH, Uerkvitz W, Tanaka K, Hendil KB: Human proteasome subunits from 2-dimensional gels identified by partial sequencing. Biochem Biophys Res Commun. 1995 Feb 27;207(3):1059.
8066462	Akiyama K, Yokota K, Kagawa S, Shimbara N, Tamura T, Akioka H, Nothwang HG, Noda C, Tanaka K, Ichihara A: cDNA cloning and interferon gamma down-regulation of proteasomal subunits X and Y. Science. 1994 Aug 26;265(5176):1231-4.

# Drug_Target_1_HGNC_ID:
HGNC:9542

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
4102

# Drug_Target_1_Locus:
14q11.2

# Drug_Target_1_Molecular_Weight:
22897

# Drug_Target_1_Name:
Proteasome subunit beta type 5

# Drug_Target_1_Number_of_Residues:
208

# Drug_Target_1_PDB_ID:
1IRU

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00227	Proteasome

# Drug_Target_1_Protein_Sequence:
>Proteasome subunit beta type 5
MLHGTTTLAFKFRHGVIVAADSRATAGAYIASQTVKKVIEINPYLLGTMAGGAADCSFWE
RLLARQCRIYELRNKERISVAAASKLLANMVYQYKGMGLSMGTMICGWDKRGPGLYYVDS
EGNRISGATFSVGSGSVYAYGVMDRGYSYDLEVEQAYDLARRAIYQATYRDAYSGGAVNL
YHVREDGWIRVSSDNVADLHEKYSGSTP

# Drug_Target_1_Reaction:
Cleavage of peptide bonds with very broad specificity INHIBITOR Mercurial reagent; Inhibitor of serine endopeptidase

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. May catalyze basal processing of intracellular antigens

# Drug_Target_1_SwissProt_ID:
P28074

# Drug_Target_1_SwissProt_Name:
PSB5_HUMAN

# Drug_Target_1_Synonyms:
EC 3.4.25.1
Macropain epsilon chain
Multicatalytic endopeptidase complex epsilon chain
Proteasome chain 6
Proteasome epsilon chain
Proteasome subunit MB1
Proteasome subunit X
Proteasome subunit beta type 5 precursor

# Drug_Target_1_Theoretical_pI:
8.68

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17591945	Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ: Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007 Nov 1;110(9):3281-90. Epub 2007 Jun 25.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Not Available

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
Not Available

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
Not Available

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
7290

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
Not Available

# Drug_Target_2_Name:
Proteasome subunit beta type-8

# Drug_Target_2_Number_of_Residues:
0

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
Not Available

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
Not Available

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
P28062

# Drug_Target_2_SwissProt_Name:
Not Available

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
Not Available

# Drug_Target_2_Transmembrane_Regions:
Not Available

# Drug_Target_3_Cellular_Location:
Cytoplasm

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17591945	Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ: Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007 Nov 1;110(9):3281-90. Epub 2007 Jun 25.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
PSMB1

# Drug_Target_3_GenBank_ID_Gene:
D00761

# Drug_Target_3_GenBank_ID_Protein:
220026

# Drug_Target_3_GeneCard_ID:
PSMB1

# Drug_Target_3_Gene_Name:
PSMB1

# Drug_Target_3_Gene_Sequence:
>726 bp
ATGTTGTCCTCTACAGCCATGTATTCGGCTCCTGGCAGAGACTTGGGGATGGAACCGCAC
AGAGCCGCGGGCCCTTTGCAGCTGCGATTTTCGCCCTACGTTTTCAACGGAGGTACTATA
CTGGCAATTGCTGGAGAAGATTTTGCAATTGTTGCTTCTGATACTCGATTGAGTGAAGGG
TTTTCAATTCATACGCGGGATAGCCCCAAATGTTACAAATTAACAGACAAAACAGTCATT
GGATGCAGCGGTTTTCATGGAGACTGTCTTACGCTGACAAAGATTATTGAAGCAAGACTA
AAGATGTATAAGCATTCCAATAATAAGGCCATGACTACGGGGGCAATTGCTGCAATGCTG
TCTACAATCCTGTATTCAAGGCGCTTCTTTCCATACTATGTTTACAACATCATCGGTGGA
CTTGATGAAGAAGGAAAGGGGGCTGTATACAGCTTTGATCCAGTAGGGTCTTACCAGAGA
GACTCCTTCAAGGCTGGAGGCTCAGCAAGTGCCATGCTACAGCCCCTGCTTGACAACCAG
GTTGGTTTTAAGAACATGCAGAATGTGGAGCATGTTCCGCTGTCCTTGGACAGAGCCATG
CGGCTGGTGAAAGATGTCTTCATTTCTGCGGCTGAGAGAGATGTGTACACTGGGGACGCA
CTCCGGATCTGCATAGTGACCAAAGAGGGCATCAGGGAGGAAACTGTTTCCTTAAGGAAG
GACTGA

# Drug_Target_3_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_3_General_References:
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.
2025653	Tamura T, Lee DH, Osaka F, Fujiwara T, Shin S, Chung CH, Tanaka K, Ichihara A: Molecular cloning and sequence analysis of cDNAs for five major subunits of human proteasomes (multi-catalytic proteinase complexes). Biochim Biophys Acta. 1991 May 2;1089(1):95-102.
2306472	Lee LW, Moomaw CR, Orth K, McGuire MJ, DeMartino GN, Slaughter CA: Relationships among the subunits of the high molecular weight proteinase, macropain (proteasome). Biochim Biophys Acta. 1990 Feb 9;1037(2):178-85.

# Drug_Target_3_HGNC_ID:
HGNC:9537

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
4101

# Drug_Target_3_Locus:
6q27

# Drug_Target_3_Molecular_Weight:
26490

# Drug_Target_3_Name:
Proteasome subunit beta type 1

# Drug_Target_3_Number_of_Residues:
241

# Drug_Target_3_PDB_ID:
1IRU

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00227	Proteasome

# Drug_Target_3_Protein_Sequence:
>Proteasome subunit beta type 1
MLSSTAMYSAPGRDLGMEPHRAAGPLQLRFSPYVFNGGTILAIAGEDFAIVASDTRLSEG
FSIHTRDSPKCYKLTDKTVIGCSGFHGDCLTLTKIIEARLKMYKHSNNKAMTTGAIAAML
STILYSRRFFPYYVYNIIGGLDEEGKGAVYSFDPVGSYQRDSFKAGGSASAMLQPLLDNQ
VGFKNMQNVEHVPLSLDRAMRLVKDVFISAAERDVYTGDALRICIVTKEGIREETVSLRK
D

# Drug_Target_3_Reaction:
Cleavage of peptide bonds with very broad specificity INHIBITOR Mercurial reagent; Inhibitor of serine endopeptidase

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity

# Drug_Target_3_SwissProt_ID:
P20618

# Drug_Target_3_SwissProt_Name:
PSB1_HUMAN

# Drug_Target_3_Synonyms:
EC 3.4.25.1
Macropain subunit C5
Multicatalytic endopeptidase complex subunit C5
Proteasome component C5
Proteasome gamma chain
Proteasome subunit beta type 1 precursor

# Drug_Target_3_Theoretical_pI:
8.29

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17591945	Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ: Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007 Nov 1;110(9):3281-90. Epub 2007 Jun 25.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
Not Available

# Drug_Target_4_GenBank_ID_Protein:
Not Available

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
Not Available

# Drug_Target_4_Gene_Sequence:
Not Available

# Drug_Target_4_General_Function:
Not Available

# Drug_Target_4_General_References:
Not Available

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
7288

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
Not Available

# Drug_Target_4_Name:
Proteasome subunit beta type-9

# Drug_Target_4_Number_of_Residues:
0

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
Not Available

# Drug_Target_4_Protein_Sequence:
Not Available

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
Not Available

# Drug_Target_4_Specific_Function:
Not Available

# Drug_Target_4_SwissProt_ID:
P28065

# Drug_Target_4_SwissProt_Name:
Not Available

# Drug_Target_4_Synonyms:
Not Available

# Drug_Target_4_Theoretical_pI:
Not Available

# Drug_Target_4_Transmembrane_Regions:
Not Available

# Drug_Target_5_Cellular_Location:
Cytoplasm

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17591945	Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ: Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007 Nov 1;110(9):3281-90. Epub 2007 Jun 25.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
PSMB2

# Drug_Target_5_GenBank_ID_Gene:
D26599

# Drug_Target_5_GenBank_ID_Protein:
565649

# Drug_Target_5_GeneCard_ID:
PSMB2

# Drug_Target_5_Gene_Name:
PSMB2

# Drug_Target_5_Gene_Sequence:
>606 bp
ATGGAGTACCTCATCGGTATCCAAGGCCCCGACTATGTTCTTGTCGCCTCCGACCGGGTG
GCCGCCAGCAATATTGTCCAGATGAAGGACGATCATGACAAGATGTTTAAGATGAGTGAA
AAGATATTACTCCTGTGTGTTGGAGAGGCTGGAGACACTGTACAGTTTGCAGAATATATT
CAGAAAAACGTGCAACTTTATAAGATGCGAAATGGATATGAATTGTCTCCCACGGCAGCA
GCTAACTTCACACGCCGAAACCTGGCTGACTGTCTTCGGAGTCGGACCCCATATCATGTG
AACCTCCTCCTGGCTGGCTATGATGAGCATGAAGGGCCAGCGCTGTATTACATGGACTAC
CTGGCAGCCTTGGCCAAGGCCCCTTTTGCAGCCCACGGCTATGGTGCCTTCCTGACTCTC
AGTATCCTCGACCGATACTACACACCGACTATCTCACGTGAGAGGGCAGTGGAACTCCTT
AGGAAATGTCTGGAGGAGCTCCAGAAACGCTTCATCCTGAATCTGCCAACCTTCAGTGTT
CGAATCATTGACAAAAATGGCATCCATGACCTGGATAACATTTCCTTCCCCAAACAGGGC
TCCTAA

# Drug_Target_5_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_5_General_References:
1286667	Rasmussen HH, van Damme J, Puype M, Gesser B, Celis JE, Vandekerckhove J: Microsequences of 145 proteins recorded in the two-dimensional gel protein database of normal human epidermal keratinocytes. Electrophoresis. 1992 Dec;13(12):960-9.
7918633	Nothwang HG, Tamura T, Tanaka K, Ichihara A: Sequence analyses and inter-species comparisons of three novel human proteasomal subunits, HsN3, HsC7-I and HsC10-II, confine potential proteolytic active-site residues. Biochim Biophys Acta. 1994 Oct 18;1219(2):361-8.

# Drug_Target_5_HGNC_ID:
HGNC:9539

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
4103

# Drug_Target_5_Locus:
1p34.2

# Drug_Target_5_Molecular_Weight:
22837

# Drug_Target_5_Name:
Proteasome subunit beta type 2

# Drug_Target_5_Number_of_Residues:
201

# Drug_Target_5_PDB_ID:
1IRU

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00227	Proteasome

# Drug_Target_5_Protein_Sequence:
>Proteasome subunit beta type 2
MEYLIGIQGPDYVLVASDRVAASNIVQMKDDHDKMFKMSEKILLLCVGEAGDTVQFAEYI
QKNVQLYKMRNGYELSPTAAANFTRRNLADCLRSRTPYHVNLLLAGYDEHEGPALYYMDY
LAALAKAPFAAHGYGAFLTLSILDRYYTPTISRERAVELLRKCLEELQKRFILNLPTFSV
RIIDKNGIHDLDNISFPKQGS

# Drug_Target_5_Reaction:
Cleavage of peptide bonds with very broad specificity INHIBITOR Mercurial reagent; Inhibitor of serine endopeptidase

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit has a chymotrypsin-like activity

# Drug_Target_5_SwissProt_ID:
P49721

# Drug_Target_5_SwissProt_Name:
PSB2_HUMAN

# Drug_Target_5_Synonyms:
EC 3.4.25.1
Macropain subunit C7-I
Multicatalytic endopeptidase complex subunit C7-I
Proteasome component C7- I

# Drug_Target_5_Theoretical_pI:
7.04

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Not Available

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
17591945	Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ: Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007 Nov 1;110(9):3281-90. Epub 2007 Jun 25.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
Not Available

# Drug_Target_6_GenBank_ID_Protein:
Not Available

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
Not Available

# Drug_Target_6_Gene_Sequence:
Not Available

# Drug_Target_6_General_Function:
Not Available

# Drug_Target_6_General_References:
Not Available

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
7289

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
Not Available

# Drug_Target_6_Name:
Proteasome subunit beta type 10

# Drug_Target_6_Number_of_Residues:
0

# Drug_Target_6_PDB_ID:
Not Available

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
Not Available

# Drug_Target_6_Protein_Sequence:
Not Available

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
Not Available

# Drug_Target_6_Specific_Function:
Not Available

# Drug_Target_6_SwissProt_ID:
P40306

# Drug_Target_6_SwissProt_Name:
Not Available

# Drug_Target_6_Synonyms:
Not Available

# Drug_Target_6_Theoretical_pI:
Not Available

# Drug_Target_6_Transmembrane_Regions:
Not Available

#END_DRUGCARD DB08889
